The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.
about
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promiseLong-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitisLaser scanning cytometry for the detection of neoplasia in urologic cytology specimens.Increased efficiency of detecting genetically aberrant cells by UroVysion test on voided urine specimens using automated immunophenotypical preselection of uroepithelial cells.Integrating a FISH imaging system into the cytology laboratory.Urine-based assays for the detection of bladder cancer.Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinomaBiliary confocal laser endomicroscopy real-time detection of cholangiocarcinoma.Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis.Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures.Urine cytology and adjunct markers for detection and surveillance of bladder cancer.Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic studyDetermination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancerChromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening studyStepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancerProfiling breast cancer by array CGH.Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting : the Papanicolaou Society of Cytopathology Practice Guidelines Task Force.Cytometry and genetics.Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analysesThe fascinating story of urine examination: From uroscopy to the era of microscopy and beyond.The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.Significant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma.Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridizationTargeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand.Urine and bladder washing cytology for detection of urothelial carcinoma: standard test with new possibilities.A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreementBasics of cytology.Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice.Fluorescence in situ hybridization: a multitarget approach in diagnosis and management of urothelial cancer.Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens.UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary studyCorrelation of histology with biomarker status after photodynamic therapy in Barrett esophagus.Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization.Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation.Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.Translational Research Working Group developmental pathway for biospecimen-based assessment modalities.Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears.
P2860
Q26775990-E188D6AA-BDE1-4F2F-8354-E6B84257ED1FQ28263151-218FEEE8-A48D-4393-8C7E-0C713DB84A97Q33202016-A9A5260E-456D-40E1-AC80-728842CFF7B5Q33316979-3442D959-AB78-4FB3-BC6E-D4810979EEA7Q33570471-35AD8304-EEB1-414D-8D1D-BAB64D715233Q33643957-1DE1F71E-0C7C-49CA-B26D-B6561768E4BFQ33686437-3A53A2C2-E42E-4441-93CF-BF88390B6759Q33939845-B4C5793C-8097-4943-A14A-AB00976264ECQ34016615-979DF750-A86F-4416-90A2-7A46B038D64FQ34027102-2855E1CC-35B0-4BE5-AD88-EABCF0B2D689Q34073973-3ECCC87A-44DF-4C01-B758-26BFBA2E145AQ34361348-6D642D77-8523-4042-86EA-B7189B95D76AQ34515117-ACBB9002-12DB-44D1-BA82-B526E77E0BABQ34587111-4CC5E28A-3C56-4297-BFA3-1D2F50B65517Q34838223-377E63FC-284F-4EAF-A358-715BDDB96E8CQ35130676-39FA8AF7-0BAF-4914-BE44-4A18F2BF570BQ35219041-7F81C5C7-D929-41FE-AF12-90AD8140376DQ35616607-39DCC6B4-229C-4195-BE74-3BCF6145FC97Q35679860-BEA4752B-86FF-446B-B484-A63FA798AE27Q35747661-7DF0862F-FBF9-436F-88E7-834252739823Q35782652-23E4C75E-9508-442A-A367-4F43F826A99DQ35790135-182ED635-E09C-4FCE-B869-D356BAB0A3F9Q35865635-CF022DD2-E16E-40F6-B020-2880ED534E5DQ35870267-93E07BF6-5D7B-40A4-B1BA-4ACB23D1C7FFQ35982594-85429B4C-055C-4C2F-930D-D75B38E3E994Q36177679-6FD5C879-BBD6-40C3-BFA5-E0FD796C7A82Q36340124-166D7EFA-BA9A-43F6-AA9E-7ED30AA4AB99Q36358049-5FA9250B-A27F-4799-B311-4E19CF042780Q36425161-3031B22E-453A-4FD0-95C8-3FC0511783B4Q36532210-40E0C2BF-EB7C-4C47-AA15-E957962E2B39Q36691710-D7125E64-1DCB-4FAB-A4B4-783956D11CD9Q36757897-A41F9FB6-A375-4DE5-AD9A-3EC542FAF872Q36936816-14CE2EF5-F00F-4D7A-837C-B4F0D703B128Q37085332-5CEA7588-BB4B-4B32-9FC4-716536C7A729Q37216677-20224F9F-F1B4-4D2C-A6E7-ACCB3B32ECE9Q37222499-338104A2-5E46-4F46-997E-FEEBF458FE42Q37238810-2B6F6B4A-BFEA-4135-B319-CC47A9FC8E7FQ37279014-B3F477D4-FF11-4D20-9E3E-3CDBE76F3A60Q37331597-61177D98-86AE-4FAA-9E68-0BB97830337AQ37406155-E28083B2-303F-4E3F-80B5-29D952BE3F7E
P2860
The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
The development of a multitarg ...... urothelial carcinoma in urine.
@en
The development of a multitarg ...... urothelial carcinoma in urine.
@nl
type
label
The development of a multitarg ...... urothelial carcinoma in urine.
@en
The development of a multitarg ...... urothelial carcinoma in urine.
@nl
prefLabel
The development of a multitarg ...... urothelial carcinoma in urine.
@en
The development of a multitarg ...... urothelial carcinoma in urine.
@nl
P2093
P2860
P1476
The development of a multitarg ...... urothelial carcinoma in urine.
@en
P2093
H M Burkhardt
I A Sokolova
K C Halling
R B Jenkins
S A Seelig
P2860
P304
P356
10.1016/S1525-1578(10)60625-3
P577
2000-08-01T00:00:00Z